標(biāo)題: Titlebook: Drug Delivery and Targeting; Monika Sch?fer-Korting,Ulrich S. Schubert Book 2024 The Editor(s) (if applicable) and The Author(s), under ex [打印本頁] 作者: firearm 時(shí)間: 2025-3-21 18:15
書目名稱Drug Delivery and Targeting影響因子(影響力)
書目名稱Drug Delivery and Targeting影響因子(影響力)學(xué)科排名
書目名稱Drug Delivery and Targeting網(wǎng)絡(luò)公開度
書目名稱Drug Delivery and Targeting網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Delivery and Targeting被引頻次
書目名稱Drug Delivery and Targeting被引頻次學(xué)科排名
書目名稱Drug Delivery and Targeting年度引用
書目名稱Drug Delivery and Targeting年度引用學(xué)科排名
書目名稱Drug Delivery and Targeting讀者反饋
書目名稱Drug Delivery and Targeting讀者反饋學(xué)科排名
作者: 我要威脅 時(shí)間: 2025-3-21 20:34
Anwendung der Verhaltensmedizinities in treating and healing diseases. In addition to viral gene transfer, the overwhelming power of non-viral mRNA-based vaccines is driving the development of novel gene transporters. Thereby, various nucleic acids such as DNA (pDNA) or RNA (mRNA, siRNA, miRNA, gRNA, or ASOs) need to be delivered作者: Spartan 時(shí)間: 2025-3-22 01:34 作者: Coma704 時(shí)間: 2025-3-22 06:09
https://doi.org/10.1007/978-3-662-48124-0ng them into patient-friendly formulations: they are often unstable and have a tendency to aggregate or degrade upon storage. As a result, the vast majority of protein actives are delivered parenterally as solutions, which has a number of disadvantages in terms of cost, accessibility, and patient ex作者: 邊緣 時(shí)間: 2025-3-22 10:08 作者: 盡忠 時(shí)間: 2025-3-22 13:47
Verfahren der Fertigungssteuerungty against infections and diseases. According to the types of infectious diseases and the required immunity, adjuvants with various acting mechanisms have been designed and applied in human vaccines. In this chapter, we introduce the advances in vaccine adjuvants based on nanomaterials and small mol作者: 盡忠 時(shí)間: 2025-3-22 17:03
Verfahren der Fertigungssteuerunguding drug-loaded polymeric microparticles, implants (preformed and in situ forming), oil-based solutions, and aqueous suspension have been established. In this chapter, we summarize all the marketed technology platforms and discuss their challenges regarding development including but not limited to作者: 性行為放縱者 時(shí)間: 2025-3-22 22:09 作者: bourgeois 時(shí)間: 2025-3-23 05:27
Steuerungsrelevante Fertigungsmerkmaleiological action of drug delivery systems has led to a better insight into the design principles of drug delivery systems. TEM can be applied for particle characterization, for the visualization of the uptake and intracellular pathways of drug vehicles in cells and tissues and more recently can be a作者: febrile 時(shí)間: 2025-3-23 05:57
Peter Eberl,Malte Frederik M?lleritates the transport of nutrients into the central nervous system (CNS) and exchanges metabolites but restricts passage of blood-borne neurotoxic substances and drugs/xenobiotics into CNS. BBB plays a crucial role in maintaining the homeostasis and normal physiological functions of CNS but severely 作者: 似少年 時(shí)間: 2025-3-23 09:46
Stephanie Porschen-Hueck,Judith Neumerbe used for cancer therapy. Traditionally, strategies such as PEGylation have been employed to reduce (the kinetics of) nanoparticle uptake by immune cells, to endow them with long circulation properties, and to enable them to exploit the Enhanced Permeability and Retention (EPR) effect to accumulat作者: Insensate 時(shí)間: 2025-3-23 15:09
Rolf Brühl,J?rn S. Basel,Max Kuryvery, especially to posterior segment tissues, has been challenging. This chapter describes the anatomical and physiological challenges associated with ocular drug delivery before discussing constraints with regard to formulation parameters. Finally, it gives an overview of advanced drug delivery te作者: 心痛 時(shí)間: 2025-3-23 21:16 作者: MIME 時(shí)間: 2025-3-23 22:24 作者: 大洪水 時(shí)間: 2025-3-24 03:10 作者: delta-waves 時(shí)間: 2025-3-24 07:21
https://doi.org/10.1007/978-3-031-52864-4Drug carrier interactions; drug targeting; anticancer drugs; vaccines; small molecules; proteins; nucleic 作者: 雪上輕舟飛過 時(shí)間: 2025-3-24 11:05 作者: GEON 時(shí)間: 2025-3-24 17:31
Drug Delivery and Targeting978-3-031-52864-4Series ISSN 0171-2004 Series E-ISSN 1865-0325 作者: Intruder 時(shí)間: 2025-3-24 22:09 作者: elucidate 時(shí)間: 2025-3-25 02:27 作者: 勤勉 時(shí)間: 2025-3-25 03:42
Book 2024ery and – more recently – drug targeting. This is in particular relevant with the new generation of drugs acting on the immune system and tumors. These are quite often accompanied by major adverse reactions. Safe therapy is, therefore, an important area of research, in particular in chronic diseases作者: objection 時(shí)間: 2025-3-25 10:07 作者: 不感興趣 時(shí)間: 2025-3-25 15:34
Steuerungsrelevante Fertigungsmerkmaleto optimize imaging quality of soft matter samples, highlights possibilities to study certain aspects of drug delivery applications, and finally provides a short introduction to high-resolution characterization possibilities which recently emerged.作者: obtuse 時(shí)間: 2025-3-25 16:55
Visualization of Nanocarriers and Drugs in Cells and Tissuee lifetime imaging. These techniques rely on the sensitive and quantitative detection of the topically applied drug delivery systems and active substances, either by exploiting their molecular properties or by introducing environmentally sensitive probes that facilitate their detection.作者: 食料 時(shí)間: 2025-3-25 23:22 作者: Rinne-Test 時(shí)間: 2025-3-26 00:16 作者: Minuet 時(shí)間: 2025-3-26 06:46 作者: Valves 時(shí)間: 2025-3-26 11:09 作者: 悶熱 時(shí)間: 2025-3-26 14:50 作者: 思考而得 時(shí)間: 2025-3-26 18:21
Rolf Brühl,J?rn S. Basel,Max Kuryh ocular drug delivery before discussing constraints with regard to formulation parameters. Finally, it gives an overview of advanced drug delivery technologies with a specific focus on recently marketed and late-stage clinical trial products.作者: 事物的方面 時(shí)間: 2025-3-27 00:04 作者: gregarious 時(shí)間: 2025-3-27 01:40
Anwendung der Verhaltensmedizin, requiring a transporter due to their high molar mass and negative charge in contrast to classical agents. This chapter presents the specific biological hurdles for using nucleic acids and shows how new materials can overcome these.作者: 煞費(fèi)苦心 時(shí)間: 2025-3-27 07:51
Verfahren der Fertigungssteuerungecules. By reviewing the immune mechanisms induced by adjuvants with different characteristics, we aim to establish structure–activity relationships between the physicochemical properties of adjuvants and their immunostimulating capability for the development of adjuvants for more effective preventative and therapeutic vaccines.作者: forecast 時(shí)間: 2025-3-27 10:44
Verfahren der Fertigungssteuerung controlling drug release, particle size, stability, sterilization, scale-up manufacturing, etc. Finally, we discuss important criteria to consider for the successful development of long-acting injectables.作者: 讓步 時(shí)間: 2025-3-27 16:38 作者: 聯(lián)邦 時(shí)間: 2025-3-27 18:37 作者: 衣服 時(shí)間: 2025-3-27 23:57
Peter Eberl,Malte Frederik M?ller have been approved by regulatory agencies for clinical applications. This chapter will overview the strategies and technologies/approaches for brain drug delivery and discuss some of the recent advances in the field.作者: 哺乳動物 時(shí)間: 2025-3-28 05:23 作者: 樹上結(jié)蜜糖 時(shí)間: 2025-3-28 09:41
Von der Quantenphysik zum Bewusstseineting approaches, with a particular emphasis on nanoparticles, comparing targeted and non-targeted formulations for pulmonary administration. Finally, the potential of inhaled sphingolipids in the context of respiratory diseases is briefly discussed, highlighting their promising prospects in the field.作者: PUT 時(shí)間: 2025-3-28 11:16 作者: 殺死 時(shí)間: 2025-3-28 17:09 作者: Nutrient 時(shí)間: 2025-3-28 19:38
Nanomedicine – Immune System Interactions: Limitations and Opportunities for the Treatment of Cancerd opportunities of immune cell targeting with nanoparticles, and we discuss how nanoparticle-based drug delivery to specific immune cell populations in tumors as well as in secondary myeloid and lymphoid organs (such as bone marrow, lymph nodes, and spleen) can be leveraged to boost the efficacy of cancer immunotherapy.作者: 放牧 時(shí)間: 2025-3-29 02:37
Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivereting approaches, with a particular emphasis on nanoparticles, comparing targeted and non-targeted formulations for pulmonary administration. Finally, the potential of inhaled sphingolipids in the context of respiratory diseases is briefly discussed, highlighting their promising prospects in the field.作者: Surgeon 時(shí)間: 2025-3-29 04:05 作者: 殺菌劑 時(shí)間: 2025-3-29 10:35 作者: 存在主義 時(shí)間: 2025-3-29 15:01
Anwendung der Verhaltensmedizincochemical solvent characteristics like water miscibility, viscosity, and vapor pressure for the selection of the formulation process, and for particle characteristics. New alternative solvents will be introduced for PLGA nanoparticle formation and compared regarding particle characteristics and bio作者: 不連貫 時(shí)間: 2025-3-29 19:02 作者: declamation 時(shí)間: 2025-3-29 19:59 作者: Dorsal-Kyphosis 時(shí)間: 2025-3-30 01:37
Property Directed Abstract Interpretationhat delivers nucleic acids including RNA to mitochondria is required, but efforts in this area have been limited compared to research targeting the nucleus and cytoplasm. This contribution provides an overview of mitochondria-targeted gene therapy strategies and discusses studies that have attempted作者: 明確 時(shí)間: 2025-3-30 07:08 作者: Encephalitis 時(shí)間: 2025-3-30 12:13 作者: 稀釋前 時(shí)間: 2025-3-30 16:18 作者: HAVOC 時(shí)間: 2025-3-30 19:32
New Therapeutic Options in Pulmonal Diseases: Sphingolipids and Modulation of Sphingolipid Metabolisiscussed. Only such an understanding opens up the possibility of developing new therapeutic strategies with the aim of correcting the imbalance in sphingolipid metabolism and signaling. Such delivery strategies have already been studied in animal models of these lung diseases, demonstrating that tar作者: Ornithologist 時(shí)間: 2025-3-30 21:02
RNA Delivery to Mitochondriahat delivers nucleic acids including RNA to mitochondria is required, but efforts in this area have been limited compared to research targeting the nucleus and cytoplasm. This contribution provides an overview of mitochondria-targeted gene therapy strategies and discusses studies that have attempted
